Protalix BioTherapeutics, Inc. PLX 41.96
Health Care · NYSE · Data as of 2026-08-12
Protalix BioTherapeutics, Inc. (PLX) has delivered +16.0% annualized revenue growth, n/a earnings growth, and n/a dividend growth over 10 years of data. Ranked #1330 of 1968 stocks overall and #162 of 260 in the Health Care sector by Steady Score.
Industry
Biological Products
Steady Score
41.96
Overall Rank
#1330 / 1968
Sector Rank
#162 / 260
Revenue CAGR
+16.0%
Earnings CAGR
-
Dividend CAGR
-
?
E/R CAGR Ratio
-
Revenue
Earnings
Dividends
Free Cash Flow
Margin
NET Margin
FCF Margin
Payout Ratio
Payout Ratio
FCF Payout Ratio